Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 354 • 2015 ACR/ARHP Annual Meeting
Association Between Bone and Clinical Parameters in Ankylosing Spondylitis
Vladimira Boyadzhieva¹, Mariana Ivanova², Nikolay Stoilov¹, Rumen Stoilov³, Rasho Rashkov⁴, Didier Hans⁵ and Rozier Berengere⁵, ¹Rheumatology, University Hospital (MHAT) St Ivan Rilski, Sofia, Bulgaria, ²University Hospital "St. Iv. Rilski", Clinic of Rheumatology, Sofia, Bulgaria, ³University Hospital (MHAT) St Ivan Rilski, Sofia, Bulgaria, ⁴Department of Rheumatology, MHAT Sveti Ivan Rilski, Sofia, Bulgaria, ⁵Center of Bone Diseases, Lausanne University Hospital, Lausanne, Switzerland
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory rheumatological disease of unknown origin that primarily affects the axial skeleton, including the sacroiliac joints and spine,…
Abstract Number: 1629 • 2015 ACR/ARHP Annual Meeting
Non-Interventional Clinical Study Investigating the Use of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis in Germany – 3rd Interim Analysis
Matthias H. Thomas¹, Klaus Krüger², Pee Aries³, Martin Bohl-Buehler⁴, Jan Brandt-Juergens⁵, Verena Rickert⁶ and Siegfried Wassenberg⁷, ¹Medical Affairs, MSD Sharp & Dohme GmbH, Bünde, Germany, ²Praxiszentrum St. Bonifatius, München, Germany, ³Rheumatologie im Struenseehaus, Hamburg, Germany, ⁴Friedrich-Ebert-Str. 35, Rheumahaus, Potsdam, Germany, ⁵Praxis Brandt-Juergens/Karberg, Berlin, Germany, ⁶Medical Affairs, MSD Sharp&Dohme GmbH, Haar, Germany, ⁷Fachkrankenhaus, Ratingen, Germany
Background/Purpose: Golimumab (GOL) has shown its efficacy and safety in various randomized clinical trials with accurately selected patients. Data from daily clinical practice in Germany…
Abstract Number: 1747 • 2015 ACR/ARHP Annual Meeting
Predictors of Survival on Anti-TNF in an Observational Cohort of Patients with Ankylosing Spondylitis: The Role of MRI Parameters of Inflammation and Structural Damage
Walter Maksymowych¹, Zheng Zhao², Stephanie Wichuk¹, Praveena Chiowchanwisawakit³, Robert G Lambert⁴, Sasha Bernatsky⁵, Barbara Conner-Spady¹, Donald Spady¹ and Susanne Juhl Pedersen⁶, ¹Medicine, Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, Chinese PLA General Hospital, Beijing, China, ³Rheumatology, Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand, ⁴Radiology, Radiology, University of Alberta, Edmonton, AB, Canada, ⁵Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ⁶Copenhagen Center for Arthritis Research, Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: There has been no data reported evaluating MRI parameters of inflammation and structural damage. We aimed to identify factors influencing survival on anti-TNF therapy…
Abstract Number: 2882 • 2015 ACR/ARHP Annual Meeting
Baseline Extent of Damage at the Spine Predicts Radiographic Progression in Korean Patients Using Golimumab for Ankylosing Spondylitis
Jeong Seok Lee¹, Dae Young Yu², Stephen Xu³ and Eun Young Lee⁴, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul National University Hospital, Seoul, South Korea, ²Medical Affairs, Janssen Korea, Seoul, South Korea, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
Background/Purpose: Ankylosing spondylitis (AS) is a chronic rheumatic disease associated with radiographic damage of the spine. Golimumab had consistent efficacy in controlling disease activity through…
Abstract Number: 591 • 2015 ACR/ARHP Annual Meeting
Rosuvastatin Improves Endothelial Function in Patients with Inflammatory Joint Diseases, Longitudinal Associations with Atherosclerosis and Arteriosclerosis
Eirik Ikdahl¹, Jonny Hisdal², Silvia Rollefstad¹, Inge C Olsen³, Tore K. Kvien⁴, Terje R. Pedersen⁵ and Anne Grete Semb⁶, ¹Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Section of Vascular Investigations, Oslo University Hospital Aker, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Department of Preventive Cardiology, Ullevaal University Hospital, Oslo, Norway, ⁶Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Endothelial dysfunction is an early step in the formation of atherosclerotic lesions and can be quantified by the degree of flow mediated vasodilation (FMD)…
Abstract Number: 1686 • 2015 ACR/ARHP Annual Meeting
Body Mass Index Is Associated with Hip Arthritis in Patients with Ankylosing Spondylitis
Hyemin Jeong¹, Jiwon Hwang², Young Hee Eun¹, Eun-Jung Park³, Ji-Min Oh⁴, Hyungjin Kim⁵, Joong Kyong Ahn⁶, Jaejoon Lee¹, Chan Hong Jeon⁷, Eun-mi Koh⁸ and Hoon-Suk Cha⁹, ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³Department of Medicine, Jeju National University Hospital, Jeju University School of Medicine, Jeju, South Korea, ⁴Anyang SAM Hospital, Anyang, South Korea, ⁵Department of medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁶Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁷Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, South Korea, ⁸Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁹Division of Rheumatology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: To evaluate the clinical courses and associated factors of hip arthritis in patients with ankylosing spondylitis (AS). Methods: In this retrospective analysis, we evaluated…
Abstract Number: 1748 • 2015 ACR/ARHP Annual Meeting
Degenerative Changes at the Lumbar Spine in Patients with Axial Spondyloarthritis and Non-Specific Mechanical Low Back Pain: A Magnetic Resonance Imaging Study
Serkan Senol¹, Gamze Kilic², Sevgi Baspinar², Erkan Kilic³ and Salih Ozgocmen⁴, ¹Division of Neuroradiology, Erciyes University, Faculty of Medicine, Radiology, Kayseri, Turkey, ²Dept. PRM, Erciyes University, Faculty of Medicine,Division of Rheumatology, Kayseri, Turkey, ³Dept PRM, Erciyes University, Faculty of Medicine,Division of Rheumatology, Kayseri, Turkey, ⁴Dept.PRM, Erciyes University, Faculty of Medicine,Division of Rheumatology, Kayseri, Turkey
Background/Purpose: Magnetic resonance imaging (MRI) has become an invaluable tool for early diagnosis of axial spondyloarthritis (axSpA) and several MRI-based studies have identified SpA-related inflammatory…
Abstract Number: 2887 • 2015 ACR/ARHP Annual Meeting
Safety and Tolerability of Secukinumab in Patients with Active Ankylosing Spondylitis: Pooled Safety Analysis of Two Phase 3, Randomized, Controlled Trials
Atul A. Deodhar¹, Dominique Baeten², Joachim Sieper³, Brian Porter⁴, Albert Widmer⁵ and Hanno Richards⁵, ¹Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³University Clinic Benjamin Franklin, Berlin, Germany, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, an anti–interleukin-17A monoclonal antibody, improved the signs and symptoms of ankylosing spondylitis (AS) in 2 Phase 3, randomized, double-blind, placebo (PBO)-controlled studies, MEASURE…
Abstract Number: 653 • 2015 ACR/ARHP Annual Meeting
Clinical Responses and Improvements in Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol
Désirée van der Heijde¹, Juergen Braun², Martin Rudwaleit³, Oana Purcaru⁴ and Arthur Kavanaugh⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Klinikum Bielefeld, Bielefeld, Germany, ⁴UCB Pharma, Brussels, Belgium, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Axial spondyloarthritis (axSpA) includes ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA).1 AS significantly affects patient (pt) workplace productivity in both performance and disease-related absenteeism.2…
Abstract Number: 1691 • 2015 ACR/ARHP Annual Meeting
The Presence of Fibromialgia May Influence the Clinimetric Evaluation of Patients with Ankylosing Spondylitis, but Has No Impact on Disease Activity Assessment
Emilio Buschiazzo¹, Natalia Zamora², Fernando Andres Sommerfleck³, Romina Rojas Tessel⁴, Mariana Benegas⁵, Pablo Arturi^6,7, Maria Elena Crespo⁴, Emilce Schneeberger⁸ and Gustavo Citera², ¹Rheumatology, Hospital Sr Del Milagro, Salta, Argentina, ²Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Rheumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁴Hospital Sr Del Milagro, Salta, Argentina, ⁵Sanatorio Mitre, Buenos Aires, Argentina, ⁶Rheumatology, Instituto de Rehabilitacion Psicofisica and Fundacion Reumatologica Argentina, Buenos Aires, Argentina, ⁷Rheumatology, Hospital Italiano de La Plata, La Plata, Argentina, ⁸Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: Fibromyalgia (FM) can be present concomitantly in patients with Ankylosing Spondylitis (AS). It may overestimate the evaluation of disease activity, resulting in more intensive…
Abstract Number: 2062 • 2015 ACR/ARHP Annual Meeting
How Reliable Is Self-Evaluation of Symptoms of Inflammatory Back Pain By Patients?
Denis Poddubnyy¹, Inge Spiller¹, Joachim Sieper¹ and Martin Rudwaleit^1,2, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Klinikum Bielefeld, Bielefeld, Germany
Background/Purpose: Inflammatory back pain (IBP) is regarded as an important clinical parameter of axial spondyloarthritis (axSpA) and is often used in a diagnostic approach. Usually…
Abstract Number: 2892 • 2015 ACR/ARHP Annual Meeting
Statin Treatment in Patients with Ankylosing Spondylitis
Grunde Wibetoe¹, Eirik Ikdahl¹, Tore K. Kvien², Silvia Rollefstad¹ and Anne Grete Semb³, ¹Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Patients with ankylosing spondylitis (AS) have increased risk of cardiovascular disease (CVD). In the general population, CVD risk reduction can be achieved by lipid…
Abstract Number: 2829 • 2014 ACR/ARHP Annual Meeting
Spondyloarthritis Is Associated with Increased Cardiovascular and Cerebrovascular Mortality
Nigil Haroon¹, Nisha Nigil Haroon², Ping Li³, Michael Paterson³ and Robert D. Inman⁴, ¹Toronto Western Research Institute, Toronto, ON, Canada, ²Medicine, University of Toronto, Toronto, ON, Canada, ³Institute of Clinical Evaluative Sciences, Toronto, ON, Canada, ⁴Immunlogy and Institute of Medical Science, University of Toronto and Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose OnSpA is a population-based study of spondyloarthritis (SpA) based on a provincial population of over 13 million. Patients with SpA are thought to be…
Abstract Number: 2571 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Risk of Cardiovascular Disease in Patients with Ankylosing Spondylitis with High and Low Body Mass Index
Inger Jorid Berg¹, Anne Grete Semb², Désirée van der Heijde^3,4, Tore K. Kvien⁴, Hanne Dagfinrud⁴, Jonny Hisdal^5,6 and Sella A. Provan², ¹Dep of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Section of Vascular Investigations, Oslo University Hospital Aker, Oslo, Norway, ⁶Faculty of Medicine, University of Oslo, Oslo, Norway
Background/Purpose Patients with ankylosing spondylitis (AS) have increased risk of cardiovascular disease (CVD), but the mediators of this increased risk are not known. Obesity is…
Abstract Number: 1540 • 2014 ACR/ARHP Annual Meeting
Treatment Patterns of Biologics Used in Rheumatoid Arthritis and Ankylosing Spondylitis in the US Veterans Population
Brian Sauer¹, Chia-Chen Teng¹, Tao He¹, Jianwei Leng², Chao-Chin Lu¹, Neel Shah³, David J. Harrison⁴, Derek Tang⁴ and Grant W. Cannon⁵, ¹Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Salt Lake City VA and University of Utah, Salt Lake Citty, UT, ³1 Amgen Center Dr, Amgen Inc., Thousand Oaks, CA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Biologics used for rheumatoid arthritis (RA) and ankylosing spondylitis (AS), including tumor necrosis factor blockers, are a key area of focus for Veterans Affairs…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].